Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Retained Earnings (2018 - 2025)

BioNexus Gene Lab's Retained Earnings history spans 8 years, with the latest figure at -$120749.0 for Q4 2025.

  • Quarterly results put Retained Earnings at -$120749.0 for Q4 2025, up 96.49% from a year ago — trailing twelve months through Dec 2025 was -$120749.0 (up 96.49% YoY), and the annual figure for FY2025 was -$120749.0, up 96.49%.
  • Retained Earnings for Q4 2025 was -$120749.0 at BioNexus Gene Lab, down from -$112547.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $1.5 million in Q1 2022 to a low of -$4.7 million in Q2 2025.
  • The 5-year median for Retained Earnings is -$465471.0 (2023), against an average of -$731346.0.
  • Peak annual rise in Retained Earnings hit 2145.12% in 2022, while the deepest fall reached 491.84% in 2022.
  • Year by year, Retained Earnings stood at $1.5 million in 2021, then crashed by 127.05% to -$409062.0 in 2022, then tumbled by 65.57% to -$677294.0 in 2023, then tumbled by 408.29% to -$3.4 million in 2024, then soared by 96.49% to -$120749.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$120749.0, -$112547.0, and -$4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.